SAN
JOSE, Calif., Nov. 8, 2022
/PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a
biotechnology company focused on the treatment and prevention of
cancer and infectious diseases, today announced a presentation
outlining the design of its ongoing breast cancer vaccine trial on
December 7, 2022, at the 2022 San
Antonio Breast Cancer Symposium.
This Symposium takes place December 6-10,
2022 in San Antonio, TX,
and is designed to provide state-of-the-art information on the
experimental biology, etiology, prevention, diagnosis, and therapy
of breast cancer and premalignant breast disease, to an
international audience of academic and private physicians and
researchers. The scientific program consists of formal
lectures by experts in clinical and basic research, selected slide
and poster presentations, forums, and case discussions.
Presentation details can be found below:
Poster ID: OT2-10-02
Poster Title: Phase I trial of an alpha-lactalbumin
vaccine in patients with operable triple-negative breast cancer
(TNBC)
Date/Time: December 7,
2022, 5:00 PM CST
About Anixa Bioscience's Breast
Cancer Vaccine
Anixa's breast cancer vaccine, currently in Phase 1 trials,
takes advantage of endogenously produced proteins that have a
function at certain times in life, but then become "retired" and
disappear from the body. One such protein is a
breast-specific lactation protein, α-lactalbumin, which is no
longer found post-lactation in normal, aging tissues, but is
present in the majority of triple-negative breast cancers.
Activating the immune system against this "retired" protein
provides preemptive immune protection against emerging breast
tumors that express α-lactalbumin. The vaccine also contains
an adjuvant that activates an innate immune response, which allows
the immune system to mount a response against emerging tumors to
prevent them from growing. This vaccine technology was
invented by Dr. Vincent Tuohy, Mort
and Iris November Distinguished Chair in Innovative Breast Cancer
Research in the Department of Inflammation and Immunity at
Cleveland Clinic's Lerner Research Institute. Dr. Tuohy is
named as inventor on the technology, which Cleveland Clinic
exclusively licensed to Anixa Biosciences. Dr. Tuohy will
receive a portion of commercialization revenues received by
Cleveland Clinic for this technology and also holds personal equity
in Anixa.
About Anixa Biosciences,
Inc.
Anixa is a clinical-stage biotechnology company with programs
addressing cancer and infectious disease. Anixa's portfolio
of therapeutics includes a cancer immunotherapy program being
developed in collaboration with Moffitt Cancer Center, which uses a
novel type of CAR-T, known as chimeric endocrine receptor T-cell
(CER-T) technology, and, with partner MolGenie GmbH, a COVID-19
program focused on compounds targeting the Mpro enzyme
of SARS-CoV-2, which is largely conserved across all recently
identified variants. The company's vaccine portfolio includes
a novel vaccine being developed in collaboration with Cleveland
Clinic to prevent breast cancer – specifically triple negative
breast cancer (TNBC), the most lethal form of the disease – as well
as a vaccine to prevent ovarian cancer. These vaccine
technologies focus on immunizing against "retired" proteins that
have been found to be expressed in certain forms of cancer.
Anixa's unique business model of partnering with world-renowned
research institutions on clinical development allows the company to
continually examine emerging technologies in complementary fields
for further development and commercialization. To learn more,
visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements: Statements that
are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form
8-K. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law. You are cautioned not to unduly rely on such
forward-looking statements when evaluating the information
presented in this press release.
Contact:
Mike
Catelani
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-presentation-on-breast-cancer-vaccine-trial-at-the-2022-san-antonio-breast-cancer-symposium-301671201.html
SOURCE Anixa Biosciences, Inc.